Abstract
Original language | English |
---|---|
Pages (from-to) | 2933-2942 |
Number of pages | 10 |
Journal | Alzheimer's and Dementia |
Volume | 19 |
Issue number | 7 |
Early online date | 2023 |
DOIs | |
Publication status | Published - Jul 2023 |
Keywords
- Alzheimer's disease
- diagnosis
- prognosis
- self-report
- subjective cognitive decline
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's and Dementia, Vol. 19, No. 7, 07.2023, p. 2933-2942.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Changes in self- and study partner?perceived cognitive functioning in relation to amyloid status and future clinical progression
T2 - Findings from the SCIENCe project
AU - Dubbelman, Mark A.
AU - Sikkes, Sietske A. M.
AU - Ebenau, Jarith L.
AU - van Leeuwenstijn, Mardou S. S. A.
AU - Kroeze, Lior A.
AU - Trieu, Calvin
AU - van Berckel, Bart N. M.
AU - Teunissen, Charlotte E.
AU - van Harten, Argonde C.
AU - van der Flier, Wiesje M.
N1 - Funding Information: The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUMC funds. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The SCIENCe project is supported by a research grant from stichting Dioraphte. W.M.F. holds the Pasman chair. PET scans were funded by research grants from AVID and Piramal Neuroimaging. W.F. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). W.F. is recipient of the EU Joint Programme–Neurodegenerative Disease Research (JPND) ADDITION project (ZonMW, #733051083). Funding Information: The Alzheimer Center Amsterdam is supported by Alzheimer Nederland and Stichting VUMC funds. Research of the Alzheimer Center Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The SCIENCe project is supported by a research grant from stichting Dioraphte. W.M.F. holds the Pasman chair. PET scans were funded by research grants from AVID and Piramal Neuroimaging. W.F. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). W.F. is recipient of the EU Joint Programme–Neurodegenerative Disease Research (JPND) ADDITION project (ZonMW, #733051083). Funding Information: M.A.D., J.L.E., M.S.S.A.L., L.A.K., C.T., and A.C.H. report no relevant disclosures. S.A.M.S. received grant support from Health Holland (LSHM19051, LSHM20084, LSHM22026‐SGF) and Zon‐MW (#7330502051 and #73305095008). S.A.M.S. provided consultancy services for Biogen, Boehringer, and Toyama. S.A.M.S. is the developer of the Amsterdam IADL Questionnaire and received license fees from Green Valley, VtV Therapeutics, Alzheon, Vivoryon, and Roche. All funding was paid to her institution. B.N.M.B. has received research support from EU‐FP7, CTMM, ZonMw, NWO, and Alzheimer Nederland. B.N.M.B. has performed contract research for Rodin, IONIS, AVID, Eli Lilly, UCB, DIAN‐TUI, and Janssen. B.N.M.B. was a speaker at a symposium organized by Springer Healthcare. B.N.M.B. has a consultancy agreement with IXICO for the reading of PET scans. B.N.M.B. is a trainer for GE. B.N.M.B. only receives financial compensation from Amsterdam UMC. C.E.T. serves on the advisory board of Roche; performed contract research for Boehringer, Roche, Toyama Fujifilm, Eisai, and Probiodrug; obtained a grant with ADxNeurosciences; and received lecture fees from Biogen and Axon Neurosciences. W.M.F.’s research programs have been funded by ZonMW, NWO, EU‐FP7, EU‐JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health∼Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes‐Strijbis fonds, stichting Equilibrio, Edwin Bouw fonds, Pasman stichting, stichting Alzheimer & Neuropsychiatrie Foundation, Philips, Biogen MA Inc, Novartis‐NL, Life‐MI, AVID, Roche BV, Fujifilm, and Combinostics. W.M.F. holds the Pasman chair. W.M.F. is recipient of ABOARD, which is a public–private partnership receiving funding from ZonMW (#73305095007) and Health∼Holland, Topsector Life Sciences & Health (PPP‐allowance; #LSHM20106). W.M.F. has performed contract research for Biogen MA Inc and Boehringer Ingelheim. W.M.F. has been an invited speaker at Boehringer Ingelheim, Biogen MA Inc, Danone, Eisai, WebMD Neurology (Medscape), and Springer Healthcare. W.M.F. is a consultant to Oxford Health Policy Forum CIC, Roche, and Biogen MA Inc. W.M.F. participated in advisory boards of Biogen MA Inc and Roche. W.M.F. is a member of the steering committee of PAVE and Think Brain Health. All funding is paid to her institution. W.M.F. was associate editor of in 2020/2021. W.M.F. is an associate editor at . Author disclosures are available in the supporting information . Alzheimer, Research & Therapy Brain Publisher Copyright: © 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
PY - 2023/7
Y1 - 2023/7
N2 - Introduction: We investigated changes in self- and study partner?reported self-perceived cognitive decline in relation to amyloid pathology and clinical progression, in a sample of cognitively normal individuals. Methods: A total of 404 participants (63???9 years, 44% female) and their study partners completed the Cognitive Change Index (CCI) yearly (0.7?6.8 follow-up years; n visits?=?1436). Baseline and longitudinal associations between (change in) CCI scores, amyloid, and clinical progression were modeled in linear mixed models and Cox regressions. Results: CCI?study partner scores of amyloid-positive individuals increased over time (B?=?1.79, 95% confidence interval [CI]?=?[0.51, 3.06]), while CCI?self scores remained stable (B?=??0.45, 95% CI?=?[?1.77, 0.87]). Ten-point higher baseline CCI?study partner (hazard ratio [HR]?=?1.75, 95% CI?=?[1.30, 2.36]) and CCI?self scores (HR?=?1.90, 95% CI?=?[1.40, 2.58]) were associated with an approximately 2-fold increased risk of progression to mild cognitive impairment or dementia. Discussion: Study partner?reported but not self-perceived complaints increase over time in amyloid-positive individuals, supporting the value of longitudinal study partner report, even in initially cognitively normal individuals.
AB - Introduction: We investigated changes in self- and study partner?reported self-perceived cognitive decline in relation to amyloid pathology and clinical progression, in a sample of cognitively normal individuals. Methods: A total of 404 participants (63???9 years, 44% female) and their study partners completed the Cognitive Change Index (CCI) yearly (0.7?6.8 follow-up years; n visits?=?1436). Baseline and longitudinal associations between (change in) CCI scores, amyloid, and clinical progression were modeled in linear mixed models and Cox regressions. Results: CCI?study partner scores of amyloid-positive individuals increased over time (B?=?1.79, 95% confidence interval [CI]?=?[0.51, 3.06]), while CCI?self scores remained stable (B?=??0.45, 95% CI?=?[?1.77, 0.87]). Ten-point higher baseline CCI?study partner (hazard ratio [HR]?=?1.75, 95% CI?=?[1.30, 2.36]) and CCI?self scores (HR?=?1.90, 95% CI?=?[1.40, 2.58]) were associated with an approximately 2-fold increased risk of progression to mild cognitive impairment or dementia. Discussion: Study partner?reported but not self-perceived complaints increase over time in amyloid-positive individuals, supporting the value of longitudinal study partner report, even in initially cognitively normal individuals.
KW - Alzheimer's disease
KW - diagnosis
KW - prognosis
KW - self-report
KW - subjective cognitive decline
UR - http://www.scopus.com/inward/record.url?scp=85146355414&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/alz.12931
DO - https://doi.org/10.1002/alz.12931
M3 - Article
C2 - 36642977
SN - 1552-5260
VL - 19
SP - 2933
EP - 2942
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 7
ER -